NCT03139370: A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718 in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAGE-A1/3/4/6
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have MAGE-A3/A6 positive tumor
Exclusions: No evidence of CNS disease by MRI or CT of the brain- see trial for details

Comments are closed.

Up ↑